Earnings

Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY

Sep 10, 2026 · 05:23 PM ET· updated 53m ago

Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from

Why It Matters

Alzamend lost more money per share than experts thought it would, and the company still has zero sales. When a company keeps losing money with no income, it needs to find a way to make products that people will buy.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ALZN1.70

+0.02 (+0.89%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.